Schedule Xylazine as a Controlled Substance

Full Title:
Combating Illicit Xylazine Act

Summary#

This bill would add xylazine (a veterinary sedative) to Schedule III of the federal Controlled Substances Act. That makes most manufacture, distribution, and non-authorized possession of xylazine a federal controlled-substance offense and brings xylazine into federal tracking systems. The bill also limits who counts as an “ultimate user” (the people allowed to possess xylazine without registering) to veterinarians, owners or caregivers of animals, and certain government animal programs. It directs agencies to help manufacturers transition, asks the Sentencing Commission to review penalties, and requires reports to Congress on illicit xylazine use.

Key changes:

  • Schedule change: Xylazine and products that contain any amount of it are added to Schedule III (federal control).
  • Who may possess without registering: Only veterinarians, pharmacies dispensing under a veterinarian prescription, animal owners/caregivers, and government animal-control or wildlife programs are treated as “ultimate users” for xylazine.
  • Transition rules: Some Schedule III requirements (security, labeling, registration) for xylazine are delayed short term to allow a transition period.
  • Tracking and reporting: Xylazine must be included in ARCOS (the DEA automated drug transaction reporting system), and DOJ/DEA/FDA must report to Congress on illicit xylazine use.
  • Sentencing review: The U.S. Sentencing Commission must review federal sentencing guidelines for offenses involving xylazine.

What it means for you#

  • Veterinarians and veterinary clinics

    • Must follow Schedule III rules for dispensing and recordkeeping for xylazine after a 60-day transition period for practitioner registration and recordkeeping.
    • May continue current lawful activities if they apply for required registration within the 60-day window.
    • Manufacturing facilities that already make xylazine are not required to immediately install new capital security changes.

  • Animal owners, caretakers, and animal-control/wildlife programs

    • May possess xylazine for animals without having to register as a controlled-substance handler, provided possession fits the bill’s listed uses (owned animal, animal under care, or authorized programs).
    • The bill says these “ultimate users” do not need to register.

  • Pharmacies and distributors

    • Pharmacies dispensing xylazine under a veterinarian’s prescription will fall under Schedule III rules and must register and follow reporting after the transition periods.
    • Distributors and manufacturers will need to report transactions involving xylazine to ARCOS.

  • Manufacturers

    • Must comply with Schedule III manufacturing rules but are given some administrative help from FDA/DEA to speed required submissions.
    • The bill temporarily delays some labeling and packaging requirements for one year.

  • Law enforcement and prosecutors

    • Will be able to charge unlawful manufacture, distribution, or possession of xylazine under federal controlled-substance laws.
    • Sentencing policy may be updated to specify penalties for xylazine-related offenses.

  • People involved in illicit drug supply

    • The presence of xylazine in the illicit drug supply would be covered by federal drug laws once scheduled; trafficking or distribution could be prosecuted under the Controlled Substances Act.

Expenses#

No publicly available information.

Possible costs or administrative impacts the bill could cause:

  • Federal agencies (DEA, FDA, Department of Justice, Sentencing Commission) will need staff time and resources to implement schedule change, handle manufacturer submissions, review sentencing guidelines, and prepare the required reports.
  • Manufacturers, distributors, and pharmacies may face compliance costs to register, adjust recordkeeping, and report to ARCOS.
  • Veterinarians and animal clinics may need to update inventory and record systems and pay registration fees where required.
  • States and local law enforcement may have additional enforcement or tracking costs.

Proponents' View#

The bill appears intended to reduce illicit availability and misuse of xylazine by bringing it under federal control and improving tracking and enforcement. Possible arguments for the bill, drawn from its provisions:

  • Scheduling xylazine would make diversion and unlawful distribution prosecutable under federal law.
  • Adding xylazine to ARCOS would create federal data on production and distribution to help identify sources and diversion points.
  • The required reports to Congress would provide information on where illicit xylazine is coming from and how it is being used, aiding policy responses.
  • Transition delays and the narrow “ultimate user” definition seek to protect legitimate veterinary and animal-care uses while the new controls take effect.

Opponents' View#

The bill text itself does not present opposition, but it raises several concerns or questions that follow from how it is written:

  • One concern is that veterinarians, animal shelters, and small clinics may face extra paperwork, registration fees, and recordkeeping costs to comply with Schedule III rules.
  • It is unclear how the scheduling will affect supply and access: the bill does not say whether legitimate veterinary supply shortages could occur or how existing inventories will be handled beyond limited transition relief.
  • The bill asks the Sentencing Commission to adjust guidelines but does not state what penalties would change; this leaves uncertainty about how criminal penalties for xylazine offenses will change in practice.
  • Adding xylazine to ARCOS and federal reporting could increase administrative burden for manufacturers and distributors and raise questions about data handling and privacy for legitimate buyers.
  • The bill does not describe funding for DEA, FDA, or other agencies to carry out the new duties, so implementation could strain existing agency resources.

What is unclear:

  • The bill does not include a fiscal estimate or detailed plan for how agencies will be funded to implement new reporting, enforcement, or regulatory duties.
  • The specific changes to sentencing ranges or penalties are not set in the bill; the Sentencing Commission must review and decide.